as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 25 Sep 2026
₹1,201.0
Change
+0.6 (0.05%)
Open
₹1,204.5
Prev. Close
₹1,200.4
Day High
₹1,207.8
Day Low
₹1,193.4
Volume Analysis
Traded
1,001,238
Delivered
611,796
Delivery %
61.1%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (0)
No signal for this stock
Weaknesses (0)
No signal for this stock
Opportunities (0)
No signal for this stock
Threats (1)
- •FII holding has been falling
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹1,222.46 | ₹1,215.13 | ₹1,208.06 | ₹1,200.73 | ₹1,193.66 | ₹1,186.33 | ₹1,179.26 |
| Fibonacci | ₹1,215.13 | ₹1,209.63 | ₹1,206.23 | ₹1,200.73 | ₹1,195.23 | ₹1,191.83 | ₹1,186.33 |
| Camarilla | ₹1,204.96 | ₹1,203.64 | ₹1,202.32 | ₹1,200.73 | ₹1,199.68 | ₹1,198.36 | ₹1,197.04 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
-4.18%
1 Week
+0.23%
1 Month
+1.95%
3 Months
-11.5%
6 Months
-0.71%
1 Year
-4.16%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹716.59
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
8.56%
Net margin 9.58% × asset turnover 0.6x × equity multiplier 1.49x
Company Overview
Sector
Healthcare
Market Cap
₹101,096 Cr
P/E (TTM)
31.4
ROE
11.2%
Book Value
₹454.0
Face Value
₹1.0
Source: Screener.in (Consolidated figures) — data as of 24 Sep 2026. Not investment advice.
TopFund Analysis
Dr. Reddy S Laboratories holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 65/100. The strongest factor is Financial Strength (100/100), while Momentum (39/100) is the weakest area to weigh before deciding. FII holding has been falling.
TopFund Score — Fundamentals Quality
65/100 — GoodData confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company's working capital requirements have reduced from 85.1 days to 67.8 days
- −Dividend payout has been low at 13.2% of profits over last 3 years
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Dr. Reddy’s signed exclusive India private-market distribution agreement for Takeda’s Qdenga; vaccine expected in 1H 2027.
Dr. Reddy’s confirms voluntary license for Gilead’s once-yearly HIV prevention drug lenacapavir.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 6,758 | 6,903 | 7,237 | 7,114 | 7,696 | 8,038 | 8,381 | 8,528 | 8,572 | 8,828 | 8,753 | 7,546 | 8,100 |
| Expenses + | 4,696 | 4,894 | 5,214 | 5,283 | 5,566 | 5,962 | 6,108 | 6,530 | 6,398 | 6,818 | 6,866 | 7,164 | 7,240 |
| Operating Profit | 2,062 | 2,008 | 2,023 | 1,831 | 2,130 | 2,076 | 2,273 | 1,998 | 2,174 | 2,010 | 1,888 | 382 | 860 |
| OPM % | 31.0% | 29.0% | 28.0% | 26.0% | 28.0% | 26.0% | 27.0% | 23.0% | 25.0% | 23.0% | 22.0% | 5.0% | 11.0% |
| Other Income + | 178 | 319 | 219 | 201 | 193 | 314 | 154 | 528 | 290 | 330 | 271 | 480 | 356 |
| Interest | 37 | 35 | 39 | 59 | 60 | 76 | 82 | 66 | 83 | 91 | 94 | 106 | 126 |
| Depreciation | 353 | 376 | 374 | 368 | 381 | 397 | 471 | 455 | 476 | 505 | 521 | 557 | 537 |
| Profit before tax | 1,850 | 1,917 | 1,829 | 1,605 | 1,883 | 1,917 | 1,874 | 2,005 | 1,905 | 1,745 | 1,543 | 200 | 553 |
| Tax % | 24.0% | 23.0% | 24.0% | 18.0% | 26.0% | 30.0% | 25.0% | 21.0% | 26.0% | 23.0% | 23.0% | -11.0% | 21.0% |
| Net Profit + | 1,405 | 1,482 | 1,381 | 1,310 | 1,392 | 1,342 | 1,404 | 1,587 | 1,410 | 1,337 | 1,190 | 221 | 436 |
| EPS in Rs | 17 | 18 | 17 | 16 | 17 | 15 | 17 | 19 | 17 | 16 | 15 | 3 | 5 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 15,023 | 15,568 | 14,196 | 14,281 | 15,448 | 17,517 | 19,048 | 21,545 | 24,670 | 28,011 | 32,644 | 33,700 | 33,228 |
| Expenses + | 11,515 | 11,983 | 11,724 | 11,930 | 12,270 | 15,040 | 15,173 | 17,778 | 18,200 | 20,078 | 24,097 | 27,247 | 28,088 |
| Operating Profit | 3,508 | 3,585 | 2,472 | 2,351 | 3,178 | 2,477 | 3,874 | 3,768 | 6,470 | 7,933 | 8,547 | 6,454 | 5,140 |
| OPM % | 23.0% | 23.0% | 17.0% | 16.0% | 21.0% | 14.0% | 20.0% | 17.0% | 26.0% | 28.0% | 26.0% | 19.0% | 15.0% |
| Other Income + | 260 | 295 | 172 | 155 | 381 | 670 | 335 | 555 | 971 | 909 | 1,119 | 1,372 | 1,437 |
| Interest | 108 | 83 | 63 | 79 | 89 | 98 | 97 | 96 | 143 | 171 | 283 | 374 | 416 |
| Depreciation | 760 | 939 | 1,027 | 1,077 | 1,135 | 1,163 | 1,229 | 1,165 | 1,250 | 1,470 | 1,704 | 2,059 | 2,119 |
| Profit before tax | 2,900 | 2,859 | 1,554 | 1,350 | 2,336 | 1,886 | 2,884 | 3,061 | 6,048 | 7,201 | 7,680 | 5,393 | 4,041 |
| Tax % | 19.0% | 26.0% | 19.0% | 32.0% | 17.0% | -7.0% | 32.0% | 29.0% | 25.0% | 23.0% | 25.0% | 23.0% | — |
| Net Profit + | 2,336 | 2,131 | 1,292 | 947 | 1,950 | 2,026 | 1,952 | 2,182 | 4,507 | 5,578 | 5,725 | 4,158 | 3,183 |
| EPS in Rs | 27 | 25 | 16 | 11 | 23 | 24 | 23 | 26 | 54 | 67 | 68 | 50 | 39 |
| Dividend Payout % | 15.0% | 16.0% | 26.0% | 35.0% | 17.0% | 21.0% | 21.0% | 23.0% | 15.0% | 12.0% | 12.0% | 16.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 9,768 | 12,484 | 12,179 | 12,489 | 13,941 | 15,516 | 17,558 | 19,129 | 23,203 | 28,171 | 33,466 | 37,808 |
| Borrowings + | 4,314 | 3,352 | 4,918 | 5,071 | 3,838 | 2,210 | 3,031 | 3,384 | 1,347 | 2,002 | 4,677 | 7,734 |
| Other Liabilities + | 4,290 | 4,408 | 4,474 | 4,706 | 4,557 | 5,414 | 5,915 | 7,149 | 7,576 | 8,523 | 9,797 | 10,951 |
| Total Liabilities | 18,457 | 20,330 | 21,654 | 22,349 | 22,418 | 23,223 | 26,588 | 29,746 | 32,209 | 38,780 | 48,023 | 56,577 |
| Fixed Assets + | 5,377 | 6,563 | 6,931 | 6,968 | 7,191 | 6,850 | 8,206 | 8,122 | 9,219 | 10,426 | 18,226 | 22,063 |
| CWIP | 529 | 772 | 3,324 | 3,470 | 2,934 | 1,535 | 1,565 | 1,293 | 1,030 | 1,419 | 2,466 | 1,460 |
| Investments | 2,248 | 3,833 | 2,110 | 2,298 | 2,587 | 2,678 | 2,212 | 2,616 | 4,986 | 4,930 | 4,051 | 5,285 |
| Other Assets + | 10,303 | 9,162 | 9,290 | 9,612 | 9,707 | 12,160 | 14,605 | 17,715 | 16,974 | 22,004 | 23,280 | 27,768 |
| Total Assets | 18,457 | 20,330 | 21,654 | 22,349 | 22,418 | 23,223 | 26,588 | 29,746 | 32,209 | 38,780 | 48,023 | 56,577 |
| Equity Capital | 85 | 85 | 83 | 83 | 83 | 83 | 83 | 83 | 83 | 83 | 83 | 84 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 2,524 | 3,263 | 2,144 | 1,803 | 2,870 | 2,984 | 3,570 | 2,811 | 5,888 | 4,543 | 4,643 | 5,674 |
| Cash from Investing Activity + | -2,370 | -1,610 | -1,890 | -1,483 | -769 | -495 | -2,255 | -2,565 | -4,109 | -4,034 | -5,785 | -6,425 |
| Cash from Financing Activity + | -433 | -1,700 | -369 | -444 | -2,133 | -2,516 | -30 | -242 | -2,686 | -376 | 1,891 | 829 |
| Net Cash Flow | -280 | -47 | -114 | -124 | -31 | -27 | 1,286 | 3 | -907 | 133 | 749 | 78 |
| CFO/OP | 88 | 111 | 110 | 88 | 106 | 149 | 107 | 94 | 108 | 83 | 78 | 109 |
| Free Cash Flow | 1,009 | 2,065 | 926 | 713 | 2,248 | 2,412 | 2,323 | 1,238 | 4,009 | 1,908 | 1,327 | 2,004 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Others | 0.18% | 0.18% | 0.17% | 0.17% | 0.16% | 0.16% | 0.29% | 0.26% | 0.25% | 0.25% | 0.24% | 0.2% |
| Public | 23.93% | 25.89% | 25.73% | 24.78% | 24.2% | 23.46% | 21.69% | 21.04% | 20.45% | 20.33% | 21.27% | 20.76% |
| Promoters | 26.66% | 26.65% | 26.65% | 26.65% | 26.64% | 26.64% | 26.64% | 26.64% | 26.64% | 26.64% | 26.63% | 26.63% |
| FII | 28.19% | 28.62% | 29.13% | 27.68% | 27.53% | 26.85% | 25.75% | 25.33% | 24.69% | 22.34% | 21.14% | 20.67% |
| DII | 21.04% | 18.65% | 18.31% | 20.72% | 21.48% | 22.89% | 25.63% | 26.73% | 27.99% | 30.44% | 30.72% | 31.75% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Dr. Reddy S Laboratories (this stock) | 101,096 | 31.4 | 2.67 | 11.2% |
| Mankind Pharma Limited | 102,225 | 47.9 | 6.27 | 13.1% |
| Aurobindo Pharma Ltd | 98,939 | 26.2 | 2.64 | 10.1% |
| Max Healthcare Ins Ltd | 98,694 | 65.9 | 9.22 | 14.7% |
| Lupin Limited | 95,788 | 16.1 | 4.26 | 28.7% |
| Manipal Health Enterpri L | 95,694 | 108.0 | — | 12.7% |
| Laurus Labs Limited | 108,438 | 99.2 | 20.44 | 18.3% |
Which Mutual Funds Hold Dr. Reddy S Laboratories?
Frequently Asked Questions about Dr. Reddy S Laboratories
Dr. Reddy S Laboratories (DRREDDY) closed at ₹1,201.0 on NSE on 25 September 2026, up 0.6 (0.05%) from the previous close.
Dr. Reddy S Laboratories trades on the NSE (National Stock Exchange of India) under the symbol DRREDDY.
Dr. Reddy S Laboratories has a trailing twelve-month P/E (price-to-earnings) ratio of 31.4.
Dr. Reddy S Laboratories has a dividend yield of 0.66%.
Dr. Reddy S Laboratories's 52-week high is ₹1,415.0 and its 52-week low is ₹1,080.0.
Dr. Reddy S Laboratories has a market capitalisation of ₹101,096 crore.
Dr. Reddy S Laboratories has a TopFund Quality Score of 65/100 (Good), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Dr. Reddy S Laboratories?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.